Cite
Mekhail T, Wood L, Bukowski R. Interleukin-2 in cancer therapy: uses and optimum management of adverse effects. BioDrugs. 2000;14(5):299-318doi: 10.2165/00063030-200014050-00003.
Mekhail, T., Wood, L., & Bukowski, R. (2000). Interleukin-2 in cancer therapy: uses and optimum management of adverse effects. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 14(5), 299-318. https://doi.org/10.2165/00063030-200014050-00003
Mekhail, T, et al. "Interleukin-2 in cancer therapy: uses and optimum management of adverse effects." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 14,5 (2000): 299-318. doi: https://doi.org/10.2165/00063030-200014050-00003
Mekhail T, Wood L, Bukowski R. Interleukin-2 in cancer therapy: uses and optimum management of adverse effects. BioDrugs. 2000 Nov;14(5):299-318. doi: 10.2165/00063030-200014050-00003. PMID: 18034575.
Copy
Download .nbib